News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lund University Release: New Paper Indicates A Potential Fifty-Percent Reduction In Cardiac Events For Prostate Cancer Patients With Pre-Existing Cardiovascular Disease When Treated With FIRMAGON® (degarelix) Compared To LHRH Agonists


2/5/2014 8:51:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAINT-PREX, Switzerland--(BUSINESS WIRE)--A paper published today in European Urology, the official journal of the European Association of Urology, indicates that the gonadotropin releasing hormone (GnRH) antagonist degarelix (brand name: FIRMAGON®), may halve the relative risk of cardiovascular (CV) events and death in men with pre-existing CV disease (CVD) compared to treatment with commonly prescribed luteinising hormone-releasing hormone (LHRH) agonists. The report is based on a pooled analysis of 2,328 men with prostate cancer from six prospective, randomised trials.1

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES